{
  "pmcid": "5710363",
  "sha256": "18a72ad3f7db956dcdd042dd5e2bdea3285e7e87b2c8dee8d338a43351d7819d",
  "timestamp_utc": "2025-11-09T23:58:51.820081+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.112800895689496,
    "reading_ease": 26.263338309386086,
    "word_count": 233
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "This randomized controlled trial evaluated echocardiographic data from the Placement of Aortic Transcatheter Valves (PARTNER) 1 Trial."
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomized to TAVR or surgical aortic valve replacement (SAVR) in PARTNER 1A (TAVR, n=321; SAVR, n=313) and TAVR or medical treatment in PARTNER 1B (TAVR, n=165)."
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligibility criteria included severe aortic stenosis, and the study was conducted across multiple centers."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomized to TAVR or surgical aortic valve replacement (SAVR) in PARTNER 1A (TAVR, n=321; SAVR, n=313) and TAVR or medical treatment in PARTNER 1B (TAVR, n=165)."
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was death or reintervention for aortic valve structural indications, assessed over a median follow-up of 3.1 years."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomization was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not specified."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Participants were randomized to TAVR or surgical aortic valve replacement (SAVR) in PARTNER 1A (TAVR, n=321; SAVR, n=313) and TAVR or medical treatment in PARTNER 1B (TAVR, n=165)."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Of 2795 patients (mean age 84.5 years, 47% female), 424 TAVR and 49 SAVR patients had 5-year echocardiogram data."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "TAVR showed early favorable hemodynamic changes, with a decrease of −2.9 mm Hg in aortic valve mean gradient, an increase of 0.028 in Doppler velocity index, and an increase of 0.09 cm² in effective orifice area, with stability over time."
      },
      "Harms": {
        "score": 1,
        "evidence": "No significant adverse events were reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT00530894."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 16,
    "max_score": 25
  }
}